NSE: CIPLA | BSE: 500087

Mid-range Performer

Download real time

1575.80 -2.40 (-0.15%)

1.5M NSE+BSE Volume

NSE 19 Sep, 2025 3:31 PM (IST)

127,287.7

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Cipla Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CIPLA, BSE:500087 Cipla Ltd.

Cipla Ltd.

07 Nov 2020

1575.80

-0.15%

Cipla (BUY): Comprehensive Q2 beat; India drives good surprise

Buy: Cipla Ltd.

Target

BOB Capital Markets Ltd.

Cipla reported a Q2 sales/EBITDA beat of 13%/17% led by (1) outperformance in India (Covid portfolio contributed ~5% sales/EBITDA) and CGA sales, and (2) cost control (13% YoY).

Deven Choksey released a Hold report for Cipla Ltd. with a price target of 1570.0 on 08 Sep, 2025.

Cipla Ltd.

07 Nov 2020

1575.80

-0.15%

Cipla

Buy: Cipla Ltd.

Target

ICICI Securities Limited

Q2 revenues grew 14.6% YoY to | 5038 crore due to 19.8% YoY growth in domestic formulations to | 2090 crore. US revenues grew 10.1% YoY to | 1049 crore. RoW markets grew 28.2% YoY to | 828 crore. EU grew 30.0% YoY to | 247 crore. API segment grew 20.4% YoY to | 189 crore. EBITDA margins improved 266 bps YoY to 23.4% on account of a sharp drop in other expenditure amid Covid, partly offset by lower gross margins due to change in product mix. Subsequently, EBITDA grew 29.4% YoY to | 1177 crore. PAT...

Cipla Ltd. is trading above all available SMAs

Cipla Ltd.

13 Oct 2020

1575.80

-0.15%

Event Update - FDA issues CRL to IV Tramadol ; Setback for specialty portfolio in US - Reduce

Sell: Cipla Ltd.

Prabhudas Lilladhar

Deven Choksey released a Hold report for Cipla Ltd. with a price target of 1570.0 on 08 Sep, 2025.

Cipla Ltd.

11 Aug 2020

1575.80

-0.15%

Cipla Limited

Results Update: Cipla Ltd.

SMC online

Cipla Q1 profit jumps 21% YoY to Rs 577 crore, beats analysts' expectations Cipla reported a 21 percent year-on-year growth in its Q1 FY21 consolidated profit at Rs 577 crore, backed by strong performance by India, emerging markets and Europe geographies and robust operating margin. Revenue from operations grew 9 percent to Rs 4346.2 crore. The OPM increased 145 bps to 24.13%. Thus the operating profit up by 16% to Rs 1048.74 crore. Other income fell 16% to Rs 65.45 crore in Q1FY'21 compared to Rs 78.37 crore in...

Deven Choksey released a Hold report for Cipla Ltd. with a price target of 1570.0 on 08 Sep, 2025.

Cipla Ltd.

09 Aug 2020

1575.80

-0.15%

Q1FY21 Result Update - Lag in revenue growth but better guidance on SG&A leads earnings upgrade - REDUCE

Sell: Cipla Ltd.

Target

Prabhudas Lilladhar

Albuterol launch unable to make major gain in US 1QFY21 revenue and PAT were higher than our estimate due to revenue spillover of India formulations, African private markets and decline in SG&A; by 25% YoY. CIPLA guided for more than 20% EBITDA margin FY21E onwards primarily led by lower SG&A; and R&D; spend. We incorporated management's...

Cipla Ltd. has an average target of 1702.60 from 10 brokers.

Cipla Ltd.

08 Aug 2020

1575.80

-0.15%

Cipla (BUY): Strong Q1 beat; stock catalysts intact BUY

Buy: Cipla Ltd.

Target

BOB Capital Markets Ltd.

Cipla reported a Q1 EBITDA beat of 42%/30% on our/consensus estimates, led by (1) Albuterol stocking in the US, (2) chronic/trade generic sales in India, and (3) cost control (27% YoY), partly non-recurring.

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla Ltd.

19 Jun 2020, 12:00AM

1575.80

-0.15%

First Light | [Sector Report] IT Services, Pidilite Industries

Buy: Cipla Ltd.

BOB Capital Markets Ltd.

IT Services: Deep Dive 2: Telecom tech spends resilient upgrade TECHM. PIDI: Lockdown weighs on growth

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla Ltd.

22 May 2020

1575.80

-0.15%

Cipla Result Review- March 2020

Hold: Cipla Ltd.

Target

Hem Securities

Cipla Ltd focuses on the development of new formulations and has a wide range of pharmaceutical products. They offer prescription drugs, bulk drugs, animal products, pesticides, a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products. The company offers drugs used for the treatment of cancer, Alzheimer's, arthritis, Parkinson's, cardiovascular diseases, drugs that prevents transmission of AIDS from mother to child, provide consulting services on preparation of products...

Deven Choksey released a Hold report for Cipla Ltd. with a price target of 1570.0 on 08 Sep, 2025.

Cipla Ltd.

20 May 2020

1575.80

-0.15%

Cipla Limited

Results Update: Cipla Ltd.

SMC online

Cipla's Profit drops 33% to Rs 248 crore; misses Street estimates Drugmaker Cipla Ltd.'s profit declined in the March quarter on account of a high base and relatively lower sales amid the coronavirus lockdown. Net profit fell 33 percent over the previous year to Rs 246 crore in the quarter ended March. The drugmaker's revenue fell 1 percent year-on-year to Rs 4,376 crore. Cipla had reported a sharp jump in its top line in the comparable quarter last year, aided by sales of a generic...

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla Ltd.

20 May 2020

1575.80

-0.15%

CIPLA LTD

Hold: Cipla Ltd.

Target

Geojit BNP Paribas

In Q4FY20, consolidated revenue declined marginally to Rs. 4,376cr, primarily impacted by weak US revenue (-25.1% YoY). However, India (Rx+Gx) business posted a 12.2% YoY growth in sales to Rs. 1,730cr. Cipla continued to perform well across key therapeutic areas, mainly due to its One India' plan of integrating 3 businesses Prescription, Trade Generics and Consumer Health. Internationally, South Africa continued its growth momentum (10.0% YoY in local currency) while holding ground in private market and OTC. The US FDA approval for generic Albuterol MDI and the successful completion of the phase 3 clinical study of generic Advair Diskus and also filing of a complex inhaler ANDA strengthened Cipla's respiratory franchise in the US...

Cipla Ltd. is trading above all available SMAs

Is Cipla Ltd. worth buying?

623 Votes:

Buy 75.76%

Sell 13.96%

Hold 10.27%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf